Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380869997> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4380869997 abstract "Representatives from academia, industry, regulatory agencies, and patient advocacy groups convened under AASLD and EASL in June 2022 with the primary goal of achieving consensus on chronic hepatitis B virus (HBV) and hepatitis delta virus (HDV) (HDV) treatment endpoints to guide clinical trials aiming to “cure” HBV and HDV. Conference participants reached agreement on some key points. The preferred primary endpoint for phase II/III trials evaluating finite treatments for chronic hepatitis B (CHB) is “functional” cure, defined as sustained HBsAg loss and HBV DNA less than lower limit of quantification (LLOQ) 24 weeks off-treatment. An alternate endpoint would be “partial cure” defined as sustained HBsAg level <100 IU/mL and HBV DNA <LLOQ 24 weeks off-treatment. Clinical trials should initially focus on patients with HBeAg-positive or negative chronic hepatitis B, who are treatment-naïve or virally suppressed on nucleos(t)ide analogues. Hepatitis flares may occur during curative therapy and should be promptly investigated and outcomes reported. HBsAg loss would be the preferred endpoint for chronic hepatitis D, but HDV RNA <LLOQ 24 weeks off-treatment is a suitable alternate primary endpoint of phase II/III trials assessing finite strategies. For trials assessing maintenance therapy, the primary endpoint should be HDV RNA <LLOQ assessed at on-treatment week 48. An alternate endpoint would be ≥2 log reduction in HDV RNA combined with normalization of alanine aminotransferase (ALT) level. Suitable candidates for phase II/III trials would be treatment-naïve or -experienced patients with quantifiable HDV RNA. Novel biomarkers (HBcrAg, HBV RNA) remain exploratory while nucleos(t)ide analogues and pegylated interferon still have a role in combination with novel agents. Importantly, patient input is encouraged early on in drug development under the FDA/EMA patient-focused drug development programs." @default.
- W4380869997 created "2023-06-17" @default.
- W4380869997 creator A5013138122 @default.
- W4380869997 creator A5051482861 @default.
- W4380869997 creator A5068028942 @default.
- W4380869997 creator A5074836130 @default.
- W4380869997 date "2023-06-21" @default.
- W4380869997 modified "2023-10-17" @default.
- W4380869997 title "Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV/HDV treatment endpoints conference" @default.
- W4380869997 doi "https://doi.org/10.1097/hep.0000000000000431" @default.
- W4380869997 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37326326" @default.
- W4380869997 hasPublicationYear "2023" @default.
- W4380869997 type Work @default.
- W4380869997 citedByCount "3" @default.
- W4380869997 countsByYear W43808699972023 @default.
- W4380869997 crossrefType "journal-article" @default.
- W4380869997 hasAuthorship W4380869997A5013138122 @default.
- W4380869997 hasAuthorship W4380869997A5051482861 @default.
- W4380869997 hasAuthorship W4380869997A5068028942 @default.
- W4380869997 hasAuthorship W4380869997A5074836130 @default.
- W4380869997 hasBestOaLocation W43808699971 @default.
- W4380869997 hasConcept C126322002 @default.
- W4380869997 hasConcept C159047783 @default.
- W4380869997 hasConcept C189490182 @default.
- W4380869997 hasConcept C203092338 @default.
- W4380869997 hasConcept C2522874641 @default.
- W4380869997 hasConcept C2775940106 @default.
- W4380869997 hasConcept C2776699657 @default.
- W4380869997 hasConcept C2777382497 @default.
- W4380869997 hasConcept C2777410769 @default.
- W4380869997 hasConcept C2780593183 @default.
- W4380869997 hasConcept C2908737250 @default.
- W4380869997 hasConcept C3020491458 @default.
- W4380869997 hasConcept C535046627 @default.
- W4380869997 hasConcept C71924100 @default.
- W4380869997 hasConcept C90924648 @default.
- W4380869997 hasConceptScore W4380869997C126322002 @default.
- W4380869997 hasConceptScore W4380869997C159047783 @default.
- W4380869997 hasConceptScore W4380869997C189490182 @default.
- W4380869997 hasConceptScore W4380869997C203092338 @default.
- W4380869997 hasConceptScore W4380869997C2522874641 @default.
- W4380869997 hasConceptScore W4380869997C2775940106 @default.
- W4380869997 hasConceptScore W4380869997C2776699657 @default.
- W4380869997 hasConceptScore W4380869997C2777382497 @default.
- W4380869997 hasConceptScore W4380869997C2777410769 @default.
- W4380869997 hasConceptScore W4380869997C2780593183 @default.
- W4380869997 hasConceptScore W4380869997C2908737250 @default.
- W4380869997 hasConceptScore W4380869997C3020491458 @default.
- W4380869997 hasConceptScore W4380869997C535046627 @default.
- W4380869997 hasConceptScore W4380869997C71924100 @default.
- W4380869997 hasConceptScore W4380869997C90924648 @default.
- W4380869997 hasLocation W43808699971 @default.
- W4380869997 hasLocation W43808699972 @default.
- W4380869997 hasLocation W43808699973 @default.
- W4380869997 hasOpenAccess W4380869997 @default.
- W4380869997 hasPrimaryLocation W43808699971 @default.
- W4380869997 hasRelatedWork W2070578716 @default.
- W4380869997 hasRelatedWork W2191973668 @default.
- W4380869997 hasRelatedWork W2377909279 @default.
- W4380869997 hasRelatedWork W2380800518 @default.
- W4380869997 hasRelatedWork W2384383732 @default.
- W4380869997 hasRelatedWork W2414717528 @default.
- W4380869997 hasRelatedWork W2774996747 @default.
- W4380869997 hasRelatedWork W4205354877 @default.
- W4380869997 hasRelatedWork W4250340554 @default.
- W4380869997 hasRelatedWork W4295787521 @default.
- W4380869997 hasVolume "Publish Ahead of Print" @default.
- W4380869997 isParatext "false" @default.
- W4380869997 isRetracted "false" @default.
- W4380869997 workType "article" @default.